BioNTech (BNTX) Q4 FY25 earnings call: guidance and Q&A

How will the mRNA therapeutics be split between BioNTech and the new company, and what kind of innovation will the new company pursue?

BioNTech's core mRNA capabilities, strategy, and pipeline remain unchanged, including COVID and mRNA oncology programs. The new company will focus on next-generation mRNA innovation, particularly in combination with AI, using basic technologies from BioNTech. It will have distinct resources and funding options, with BioNTech holding a minority stake.

“But you can imagine, Daina is -- and you are very close to that, that the field in the mRNA space is rapidly advancing. And we are seeing a lot of innovation happening, particularly in combination with AI. And we together felt really the need to address that by Ozlem and I focusing on this chapter -- on this type of endeavor to ensure that we can use basic technologies and basic IT that comes from BioNTech to build something completely new. And completely new means really next generation and we call it the next-generation everything that goes beyond the current generation.”

asked by Daina Graybosch · answered by Ugur Sahin

What is the profile for the new CEO, internal or external? How is BioNTech preparing for the T-Pam launch in endometrial cancer, and will this infrastructure serve other launches?

Ugur and Ozlem will remain through the transition. The Supervisory Board is searching for successors with strong experience in late-stage development and commercial execution. The organization is already building commercial, medical, and market access capabilities for potential launches, including T-Pam, which will support the broader pipeline.

“The focus is on leaders with strong experience in late-stage development and commercial execution, which reflects BioNTech's next phase of growth. At the same time, as you know with Annemarie and all of our commercial teams, we are already preparing the organization for these potential launches, including endometrial cancer and other programs. And we are building the commercial, medical and market access capabilities needed to support all of this pipeline coming through.”

asked by Tazeen Ahmad · answered by Ramón Zapata-Gomez

Why is the leadership transition happening now, given it's a critical time for the company with important readouts and pipeline momentum?

The transition is planned for the end of 2026, not immediately. This timing is considered optimal as the company will have numerous readouts and over 15 Phase III trials by then, requiring industrialization and scale. The plan aligns with sharpening BioNTech's strategic focus, and the existing governance and scientific leadership provide stability.

“I think from timing wise, we are talking now end of 2026 and not today, yes. So we have a clear plan for milestones and data readouts in 2026. And we believe it's really a perfect timing for transition -- transitioning because the company, at the time point end of 2026 will already have a number of readouts, important readouts, but also the number of Phase III studies that we plan end of 2026, 15-plus Phase III clinical trials. And this is really about industrialization and we need to get people on board who connect that -- connect this with the scale that is needed at that moment.”

asked by Asad Haider · answered by Ugur Sahin

Will BioNTech contribute capital to the new company, or only be a minority investor? What is the market opportunity for Goti in second-line plus squamous NSCLC if Part 1 results are replicated?

BioNTech will contribute rights and mRNA technologies, not cash, to the new company, and will be a minority investor. The new company will seek funding from other sources. For Goti, if Part 1 data (hazard ratio ~0.5) is replicated, it would be game-changing for the sizable second-line NSCLC patient population, which has seen no disruptive innovation in 30 years. Market projections will be provided after data readout.

“I think the short answer would be no. Based on what is contemplated today, BioNTech's contribution to the NewCo related to certain rights and mRNA technologies, not cash. The new company will have the ability to pursue funding from other sources, while BioNTech remains focused on advancing our late-stage pipeline and keep preparing for commercialization and further innovation in our key priorities.”

asked by Cory Kasimov · answered by Ramón Zapata-Gomez

How stable is the current late-stage and mid-stage pipeline prioritization given the upcoming management transition? Could positive Goti interim data lead to accelerated regulatory filing?

The management transition does not change strategic priorities; BioNTech remains focused on its late-stage pipeline and mRNA oncology programs. The organization's governance and scientific leadership provide stability. For Goti, if interim data replicates initial strong results, there is absolutely a potential regulatory path forward for accelerated approval.

“So depending, obviously, on the data, we will see later this year from the interim analysis of Goti study. And if we can replicate the data we have shown in the initial part of the study, there is absolutely a potential regulatory path forward for an accelerated approval.”

asked by Unknown Analyst · answered by Özlem Türeci

Why was ROSETTA Lung-02 expanded to 1,260 patients, and what data should be expected for T-Pam in endometrial cancer this year?

ROSETTA Lung-02's sample size increase for both histologies was based on ongoing assessment of available data, including from other bispecific antibody trials, to increase speed. The trial design was amended to have PFS as the primary endpoint and OS as a key secondary endpoint. For T-Pam in endometrial cancer, the company plans to submit a BLA this year based on the data package, with a confirmatory Phase III trial ongoing.

“Regarding the sample size increase in our non-small cell lung cancer study, we are constantly assessing available data or emerging data from our trials and also from other trials with this bispecific antibody class. And based on this data, we expanded the center size also to increase speed. It was an increase for both histologies. We also amended the trial design with regard to the endpoints. We have PFS now as primary endpoint and OS as key secondary endpoint, which also helps with the speed.”

asked by Yaron Werber · answered by Özlem Türeci

Will there be milestone or royalty economics tied to the IP contributed to the new company? How large is the expected step down in COVID sales, and what is the relative pressure from US, EU, and Germany?

Specific financial guidance for the new company's IP economics is not yet provided, as terms are under negotiation for the binding agreement expected by H1 2026. No material short- or mid-term financial impact is expected for BioNTech. For COVID sales, a step down is anticipated in 2026 due to market normalization. The US is a competitive market, Europe is transitioning from multiyear contracts, and Germany's direct sales model means declines directly impact the top line, unlike other regions where revenue is part of a 50% gross profit split with Pfizer.

“So thank you for the questions. So on your first question, we are not providing any specific financial guidance related to the potential answer of the related rights and mRNA technologies to the NewCo at this stage. The terms of the transaction, including any potential IP-related consideration are still under negotiation and will be defined as part of the binding agreement expected by the end of the first half of 2026. What we can say is that we do not expect a material short or midterm financial impact for BioNTech.”

asked by Asthika Goonewardene · answered by Ramón Zapata-Gomez